[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639338":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":24,"locations":18,"responsibleParty":30,"collaborators":18,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":18,"enrollmentInfo":43,"targetDuration":18,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":54,"whyStopped":18,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":18},{"fullName":5,"class":6},"Sahlgrenska University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sodium Zirconium Cyclosilicate treated","ACTIVE_COMPARATOR","Sodium Zirconium Cyclosilicate",[13],"Drug: potassium binder",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","Usual care as per judgement of treating physician",null,[20],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":18},"DRUG","potassium binder",[9],[25],{"name":26,"role":27,"phone":28,"phoneExt":18,"email":29},"Michael Liangxiong Fu","CONTACT","0739228176","michael.fu@gu.se",{"type":31,"investigatorFullName":32,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Michael Fu","Professor","100639338","phase-2-optimizing-aldosterone-receptor-antagonist-therapy-by-sodium-zirconium-cyclosili-cate-in-heart-failure--extension-opra-hf-extension-100639338",false,"NCT07576257","OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosili-cate in Heart Failure -Extension (OPRA-HF Extension)","OPRA-HF Extens","Inclusion Criteria:\n\n* 1\\. \\>70 yrs. 2. Regardless of LVEF but EF measured within past 2 years. For HFpEF echo criteria defined by ≥2 of: LV wall thickness ≥ 12 mm; LV mass index (BSA indexed LVH): male \\>115 g\u002Fm2, female \\>95 g\u002Fm2; relative wall thickness ≥0.42; E\u002Fe' ≥15 in sinus rhythm (or \\> 11 in the setting of atrial fibrillation); tricuspid regurgitation velocity \\>2.8 m\u002Fs; Left atrial volume index \\>34 ml\u002Fm2.\n\n  3\\. GFR ≥ 20 mL\u002Fmin\u002F1,73 m². 4. NYHA II-IV. 5. On optimal treatment as per physician´s judgement including ACE\u002FARB\u002FARNI, beta blockers, SGLT2 inhibitor för HFrEF\u002FHFmrEF, and SGLT2 inhibitors in HFpEF 6. Suboptimal treatment with MRA (defined as: no use or ≤ 25 mg daily 7. And one of following:\n  1. Prior hyperkalemia (S-K\\> 5.0 mmol\u002FL or P-K\\> 4.8 mmol\u002FL\\*) during MRA treatment within last 24 months, and current S-K ≤ 5.0 or P-K ≤ 4.8 mmol\u002FL\n  2. Current S-K 4.5-5.0 mmol\u002FL or P-K 4.3-4.8 mmol\u002FL, and potential risk of hyperkalemia as indicated by eGFR 30-45 ml\u002Fmin\u002F1,73 m2\n  3. Current S-K 5.1-5.9 mmol\u002FL or P-K 4.9-5.7 mmol\u002FL\n\n     * Corresponding plasma K (P-K) level is 0.2 mmol lower than serum K(S-K). Hyperkalemia is defined as P-K \\> 4,8 mmol\u002FL or S-K \\>5,0 mmol\u002FL.\n\n     Exclusion Criteria:","ALL","70 Years",{"count":44,"type":45},110,"ESTIMATED","INTERVENTIONAL",[48],"PHASE2","A multicenter, randomized, controlled study in Sweden (n=110). This study consists of 2 phases: 1) open-label run-in within approximately 2 months, and 2) randomized, double-blinded and placebo-controlled treatment for 6 months.\n\nThe open-label phase, in turn, consists of three periods: up-titration (normally 1 - 2 weeks, and longer in some cases), correction (maximum 72 hours) and maintenance (4 - 7 weeks).",[51],"Heart Failure",[53],"effect","NOT_YET_RECRUITING","2026-05-03",{"date":57,"type":58},"2026-05-08","ACTUAL",{"date":60,"type":45},"2026-09-01",{"date":62,"type":45},"2030-06-30",{"name":5,"class":6}]